Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

49 United States sites

5 France sites

5 Spain sites

4 Greece sites

4 Italy sites

4 United Kingdom sites

3 Canada sites

2 Lebanon sites

2 Germany sites

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
Near-infrared Spectroscopy in Sickle Cell Pediatric Patients During Pain Crisis and After Recovery

Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease.

Locations

1 United States site

Age

6 Years - 21 Years

Genotypes

hemoglobin SS

LEARN MORE
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)

The goal of the study is to evaluate the efficacy and safety of crizanlizumab in SCD patients with priapism.

Locations

19 United States sites

Age

> 16 Years

Genotypes

HbSS, HbSC

Phase

Phase 2

LEARN MORE
Sickle Cell Disease and CardiovAscular Risk – Red Cell Exchange Trial (SCD-CARRE)

The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.

Locations

18 United States sites

1 United Kingdom site

1 France site

Age

> 18 Years

Phase

Phase 3

LEARN MORE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.

Locations

17 United States sites

5 Nigeria sites

4 Egypt sites

4 Kenya sites

4 United Kingdom sites

3 Italy sites

2 Ghana sites

2 Oman sites

2 Saudi Arabia sites

1 France site

Age

2 Years - 14 Years

Genotypes

SCA

Phase

Phase 3

LEARN MORE
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Advocacy and Research Alliance (STAR) Trial

This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.

Locations

11 United States sites

Age

2 Years - 13 Years

Genotypes

HbSS

Phase

Phase 2

LEARN MORE
Engaging Parents of Children With Sickle Cell Anemia and Their Providers in Shared-Decision Making for Hydroxyurea (ENGAGE HU)

The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences).

Locations

11 United States sites

Age

1 Month - 5 Years

Phase

Not Applicable

LEARN MORE
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease

This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).

Locations

4 United States sites

2 Canada sites

Age

2 Years - 25 Years

Genotypes

hemoglobin SS, hemoglobin SC

Phase

Phase 2

LEARN MORE
1503 BMT CTN STRIDE Biorepository

The STRIDE Biorepository is an optional substudy available to participants in "Bone Marrow Transplantation vs Standard of Care in Patients with Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE)".

Locations

40 United States sites

Age

15 Years - 40 Years

Genotypes

Hb SS, Hb SC

LEARN MORE
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

This study consists of four parts, Parts A, B, C, and D.

Locations

11 United States sites

4 United Kingdom sites

3 Lebanon sites

Age

6 Months - 17 Years

Genotypes

HbSS

Phase

Phase 2

LEARN MORE